aTYR PHARMA INC Enters Material Definitive Agreement

TL;DR

ATYR Pharma signed a big deal, filing shows. Details to come.

AI Summary

On December 23, 2024, aTYR PHARMA INC entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this event. The company is incorporated in Delaware and is in the biological products industry.

Why It Matters

This filing indicates a significant new agreement for aTYR PHARMA INC, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement is a significant event that could carry substantial risks and rewards, requiring further analysis of the agreement's terms.

Key Players & Entities

• aTYR PHARMA INC (company) — Registrant
• December 23, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-37378 (company_id) — Commission File Number
• 20-3435077 (tax_id) — IRS Employer Identification No.
• 10240 Sorrento Valley Road, Suite 300 (address) — Principal Executive Offices
• San Diego, CA 92121 (location) — Principal Executive Offices
• ( 858 ) 731-8389 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ATYR The Nasdaq Capital M
• $65.0 million — g an aggregate offering amount of up to $65.0 million (the "Initial Shares"). As of the date

Filing Documents

• atyr-20241224.htm (8-K) — 56KB
• atyr-ex1_1.htm (EX-1.1) — 33KB
• atyr-ex5_1.htm (EX-5.1) — 30KB
• img54294278_0.jpg (GRAPHIC) — 29KB
• img54294278_1.jpg (GRAPHIC) — 29KB
• 0000950170-24-139633.txt ( ) — 322KB
• atyr-20241224.xsd (EX-101.SCH) — 26KB
• atyr-20241224_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. As previously reported, aTyr Pharma, Inc. (the "Company") is a party to the Open Market Sale Agreement, dated April 22, 2022 (the "Sales Agreement"), between the Company and Jefferies LLC ("Jefferies"). Under the Sales Agreement, the Company may offer and sell, from time to time, through Jefferies as its sales agent or principal, shares of its common stock, par value $0.001 per share (the "Common Stock"), having an aggregate offering amount of up to $65.0 million (the "Initial Shares"). As of the date hereof, the Company has offered and sold Initial Shares with an aggregate offering amount of approximately $65.0 million pursuant to the Sales Agreement. On December 23, 2024, the Company and Jefferies entered into Amendment No. 1 to the Sales Agreement ("Amendment No. 1" and, together with the Sales Agreement, the "Amended Sales Agreement") to provide for an increase in the aggregate offering amount under the Sales Agreement such that the Company may offer and sell additional shares of Common Stock having an aggregate offering up to, among other things, the amount registered by the Company pursuant to a prospectus supplement (such additional shares, the "Additional Shares" and, together with the "Initial Shares," the "Shares") under the Amended Sales Agreement. The terms and conditions of the Sales Agreement otherwise remain unchanged. The Company is not obligated to sell any Shares under the Amended Sales Agreement. Subject to the terms and conditions of the Amended Sales Agreement, Jefferies will use commercially reasonable efforts, consistent with its normal sales and trading practices and applicable laws and regulations, to sell Shares from time to time based upon the Company's instructions, including any price, time or size limits or other customary parameters or conditions the Company may specify, subject to certain limitations. Under the Amended Sales Agreement, Jefferies may sell Shares by any method

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Amendment No. 1 to Open Market Sale Agreement, dated December 23, 2024, by and among aTyr Pharma, Inc. and Jefferies LLC. 5.1 Opinion of Cooley LLP . 23.1 Consent of Cooley LLP (included in Exhibit 5.1) . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATYR PHARMA, INC. By: /s/ Jill M. Broadfoot Jill M. Broadfoot Chief Financial Officer Date: December 23, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR